UCB’s Bimekizumab to reshape psoriasis market
Dec 12, 2020
1 min read
The $ 20+ billion Psoriasis treatment market has been dominated by AbbVie's Humira.
But things might change soon.
After beating J&J’s Stelara and AbbVie’s Humira, UCB’s Bimekizumab now wins over Novartis’s Cosentyx, with potential to reshape busy psoriasis market.
Comments